首页>投融资
Adaptive Phage Therapeutics
收并购
Adaptive Phage Therapeutics Inc is a clinical-stage company founded to provide an effective therapeutic response to the global rise of multi-drug resistant (MDR) pathogenic bacteria.In June 2023, Adaptive Phage Therapeutics received a $12 million upfront investment.In October 2022, Adaptive Phage Therapeutics Inc was awarded $5 million by Defense Health Agency.In April 2022, Adaptive Phage Therapeutics Inc announced that the AMR Action Fund has joined an existing $41 million Series B round as a co-investor.In May 2021, Adaptive Phage Therapeutics announced closing of $40.75 million Series B investment.In October 2019, the company raised approximately $7 million in an oversubscribed, non-brokered financing
基本信息
-
公司全称Adaptive Phage Therapeutics Inc
-
类型临床阶段生物药研发商
-
产业领域药品研发/制造、研发制造服务、检测服务、生物药
-
公司人数51~100人
-
地址22 Firstfield Road Suite 125 GAITHERSBURG MARYLAND 20878; US; Telephone: +12408992532;
-
联系电话1-844-972-0500
-
邮箱Info@aphage.com
-
成立时间2017-01-01
投融资
-
2024-03-18收并购未透露BIOMx
-
2023-06-13B轮1200万美元AMR Action FundDeerfield
-
2022-10-04未透露500万美元Defense Health Agency
-
2022-04-04B轮2000万美元AMR Action Fund
-
2021-05-11B轮4075万美元DeerfieldMayo Clinic
-
2020-08-05债权融资700万美元Mayo Clinic
-
2020-01-08捐赠/众筹/授予1020万美元United States Department of Defense
-
2019-10-07未透露700万美元Alexandria Venture Investments
- 加载更多
相关投融资企业
收并购
Adaptive Phage Therapeutics Inc is a clinical-stage company founded to provide an effective therapeutic response to the global rise of multi-drug resistant (MDR) pathogenic bacteria.In June 2023, Adaptive Phage Therapeutics received a $12 million upfront investment.In October 2022, Adaptive Phage Therapeutics Inc was awarded $5 million by Defense Health Agency.In April 2022, Adaptive Phage Therapeutics Inc announced that the AMR Action Fund has joined an existing $41 million Series B round as a co-investor.In May 2021, Adaptive Phage Therapeutics announced closing of $40.75 million Series B investment.In October 2019, the company raised approximately $7 million in an oversubscribed, non-brokered financing
B轮
Adaptive Phage Therapeutics Inc is a clinical-stage company founded to provide an effective therapeutic response to the global rise of multi-drug resistant (MDR) pathogenic bacteria.In June 2023, Adaptive Phage Therapeutics received a $12 million upfront investment.In October 2022, Adaptive Phage Therapeutics Inc was awarded $5 million by Defense Health Agency.In April 2022, Adaptive Phage Therapeutics Inc announced that the AMR Action Fund has joined an existing $41 million Series B round as a co-investor.In May 2021, Adaptive Phage Therapeutics announced closing of $40.75 million Series B investment.In October 2019, the company raised approximately $7 million in an oversubscribed, non-brokered financing
未透露
Adaptive Phage Therapeutics Inc is a clinical-stage company founded to provide an effective therapeutic response to the global rise of multi-drug resistant (MDR) pathogenic bacteria.In June 2023, Adaptive Phage Therapeutics received a $12 million upfront investment.In October 2022, Adaptive Phage Therapeutics Inc was awarded $5 million by Defense Health Agency.In April 2022, Adaptive Phage Therapeutics Inc announced that the AMR Action Fund has joined an existing $41 million Series B round as a co-investor.In May 2021, Adaptive Phage Therapeutics announced closing of $40.75 million Series B investment.In October 2019, the company raised approximately $7 million in an oversubscribed, non-brokered financing
浙公网安备33011002015279
本网站未发布麻醉药品、精神药品、医疗用毒性药品、放射性药品、戒毒药品和医疗机构制剂的产品信息